1) Compared to OXA-48, it shows impaired acti |
2) Compared to animal models, in vitro models |
3) Compared to control, polypharmacy reduced |
4) Compared to controls, patients with idiopa |
5) Compared to conventional methods, this lab |
6) Compared to free Ceph, LNFs were significa |
7) Compared to healthy individuals (8 studies |
8) Compared to low doses of gamma irradiation |
9) Compared to mice without the ΔKPQ-Scn5a m |
10) Compared to normative data during the equi |
11) Compared to other allied health profession |
12) Compared to other asthma comorbidities, ob |
13) Compared to other major ethnic groups, Whi |
14) Compared to recreational cannabis users, m |
15) Compared to reduced-intensity conditioning |
16) Compared to the AMI model group, STVNa adm |
17) Compared to the amount of research that ha |
18) Compared to the phase 3 platform trials th |
19) Compared to the pre-lockdown period, the c |
20) Compared to their normal weight peers, ove |
21) evels of insulin, C-peptide, and HOMA2-IR compared to 0-5% weight loss. |
22) for those with a provider recommendation, compared to 0.5% to 44.7% for those withou |
23) 1-SD strain treated with 6.4 mg L-1 nZVIs compared to 3.2 mg L-1 nZVIs. |
24) n Israel discussed Power/Class Asymmetry, compared to 37 per cent in Italy. |
25) (prevalence ranging from 12.8 to 13.4%), compared to 4.4-5.1% in the two U.S. |
26) d denervation-induced muscle atrophy when compared to 8-month-old mice. |
27) NPs showed efficient activity as compared to ACE, and finally, the bacteria |
28) ) respectively, suppressing the growth as compared to ACE. |
29) solated from epsin-deficient animals when compared to ApoE-/- controls. |
30) al brain tissue and cultured neurons when compared to ApoE3+/+ counterparts. |
31) gnitive impairment (MCI) or early AD when compared to ApoE4-/- subjects. |
32) (A) Root growth of SB is slightly more as compared to B-385 in control conditions in |
33) showed hypersensitivity to 200 μM Cr(VI) compared to B-385 in terms of primary root |
|